(S)-6-amino-2-methylheptan-2-ol | 165962-55-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-6-amino-2-methylheptan-2-ol
• 英文别名: (S)-6-amino-2-methyl-2-heptanol；2-Heptanol, 6-amino-2-methyl-, (6S)-；(6S)-6-amino-2-methylheptan-2-ol
• CAS: 165962-55-0
• 化学式: C₈H₁₉NO
• mdl: MFCD00127893
• 分子量: 145.245
• InChiKey: LREQLEBVOXIEOM-ZETCQYMHSA-N

物化性质

• 沸点：
  250.1±13.0 °C(Predicted)
• 密度：
  0.895±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-6-amino-2-methylheptan-2-ol 、 (4-nitrophenyl) N-[7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]carbamate 以 1,3-二甲基-2-咪唑啉酮 为溶剂， 生成 (S)-1-(5-hydroxy-1,5-dimethylhexyl)-3-[7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]urea
  参考文献：
  名称：

  [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF

  摘要：

  公开号：

  EP1630165B1
• 作为产物：
  描述：

  6-氨基-2-甲基-2-庚醇 在 Candida antarctica lipase B 作用下， 以 正庚烷 为溶剂， 反应 72.0h， 生成 (S)-6-amino-2-methylheptan-2-ol 、 (R)-6-amino-2-methylheptan-2-ol
  参考文献：
  名称：

  在30°C下高效光化学诱导的硫胺基自由基介导的脂肪胺消旋

  摘要：

  在30°C的温和条件下，在硫醇的存在下进行UV辐照可实现高效脂肪族胺的消旋化。该反应通过前手性α-氨基烷基自由基的可逆生成而进行。后者可能是由于噻吩基和胺之间的氧化还原过程或由噻吩基直接提取氢原子引起的。作为氢原子供体，硫醇起着至关重要的作用。虽然伯胺和仲胺的外消旋都是快速的过程，但叔胺的外消旋却很缓慢。暂定原理是基于光刺激的胺催化的硫醇氧化成相应的二硫化物，这使得反应介质中氢原子供体的浓度以取决于胺的性质的速率下降至痕量。

  DOI：

  10.1021/jo702241y

文献信息

• Switching from (R)- to (S)-selective chemoenzymatic DKR of amines involving sulfanyl radical-mediated racemization
  作者：Lahssen El Blidi、Nicolas Vanthuyne、Didier Siri、Stéphane Gastaldi、Michèle P. Bertrand、Gérard Gil

  DOI：10.1039/c0ob00054j

  日期：——

  Chemoenzymatic dynamic kinetic resolution (DKR) of amines involving sulfanyl radical-induced racemization happened to be the very first switchable DKR process allowing the synthesis of either (R)- or (S)-amides, in good yield and high enantiomeric excess, depending on the nature of the enzyme; the different steps of the development of (S)-selective DKR are discussed.

  化学酶动力学分辨（DKR）中的氨胺涉及硫基自由基诱导的消旋化，恰好是首个可调节的DKR过程，能够合成（R）-或（S）-酰胺，且产率良好，对映体过量高，具体取决于酶的性质；讨论了（S）选择性DKR发展的不同步骤。
• [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof
  申请人：Masuda Akira

  公开号：US20070010515A1

  公开（公告）日：2007-01-11

  Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease and also useful as an anticancer drug or as an immunological tolerance inducer for transplanted organ/transplanted bone marrow.

  这是一种通式为(1)的[1,2,4]三唑并[1,5-a]嘧啶衍生物的小说，其中(1)是其前药或其药学上可接受的盐，具有抗原呈递抑制活性，可用作预防和/或治疗器官/骨髓移植、自身免疫性疾病、过敏性疾病和/或炎症性疾病的免疫排斥和/或移植物抗宿主反应的预防和/或治疗剂，同时也可用作抗癌药物或用于移植器官/移植骨髓的免疫耐受诱导剂。
• [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF
  申请人：NIPPON KAYAKU KABUSHIKI KAISHA

  公开号：EP1630165A1

  公开（公告）日：2006-03-01

  Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease and also useful as an anticancer drug or as an immunological tolerance inducer for transplanted organ/transplanted bone marrow.

  通式（1）的新型[1,2,4]三唑并[1,5-a]嘧啶衍生物：(1) 其原药或其药学上可接受的盐，具有抗原递呈抑制活性，可作为器官/骨髓移植、自身免疫性疾病、过敏性疾病和/或炎症性疾病中免疫排斥和/或移植物与宿主反应的预防和/或治疗药物，也可作为抗癌药物或移植器官/移植骨髓的免疫耐受诱导剂。
• US7598244B2
  申请人：——

  公开号：US7598244B2

  公开（公告）日：2009-10-06
• [EN] PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED AMINES<br/>[FR] PROCEDE DE PREPARATION D'AMINES ENANTIOMERIQUEMENT ENRICHIES
  申请人：DSM NV

  公开号：WO2002020821A2

  公开（公告）日：2002-03-14

  Process for the preparation of an enantiomerically enriched acylated amine, wherein an enantiomerically enriched, substituted or unsubstituted phenylglycine amide is contacted with a mixture of enantiomers of the corresponding amine H2NCR1R2R3 where R1, R2 and R3 are not the same and each independently stands for H, CN, a substituted (cyclo)alkyl group, aryl group, alkylaryl group or arylalkyl group, a cyclic or non-cyclic heteroaryl group or heteroaryl group with one or more N, O of S atoms or (CH2)n-COR4, where n=0, 1 ...6 and R4 is OH or a substituted or unsubstituted alkyl group, aryl group, alkoxy group or amino group or where R1 and R2 (and R3) together with the C atom to which they are bound form a (bi)cyclic group which may or may not contain one or more N, O of S atoms, in the presence of a Pen-G acylase. A process for the preparation of enantiomerically enriched amine with formula H2NCR1R2R3 where R1, R2 and R3 are as defined above, wherein an acylated amine is contacted with a Pen-G acylase. Preferably a Pen-G acylase derived from Alcaligenes faecalis is applied.